Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$134.83

1.05 (0.78%)

, REGN

Regeneron

$380.46

-3.74 (-0.97%)

14:12
10/15/18
10/15
14:12
10/15/18
14:12

Fly Intel: What to watch in Johnson & Johnson earnings report

Johnson & Johnson (JNJ) is scheduled to report results of its third fiscal quarter before the market open on Tuesday, October 16, with a conference call scheduled for 8:30 am EDT. What to watch for 1. 2018 GUIDANCE: Along with its second quarter financial report in mid-July, the drug giant gave its view for FY18. J&J narrowed its FY18 EPS view to $8.07-$8.17 while lowering its yearly revenue view to $80.5B-$81.3B from $81B-$81.8B. The consensus for yearly revenue was $81.47B at the time. Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products including Tylenol analgesics and digestive health products, international beauty products primarily Neutrogena, OGX and Dr. Ci Labo, partially offset by lower sales of baby care products. Worldwide Pharmaceutical sales of $10.4B for Q2 represented an increase of 19.9% versus the prior year with an operational increase of 17.6% and a positive impact from currency of 2.3%. Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by Stelara, a biologic for the treatment of a number of immune-mediated inflammatory diseases, Zytiga, an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, Darzalex, for the treatment of patients with multiple myeloma, Imbruvica, an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, Tremfya, for the treatment of adults living with moderate to severe plaque psoriasis. Simponi/Simponi Aria a biologic for the treatment of a number of immune-mediated inflammatory diseases, Invega Sustenna/Xeplion/Trinza/Trevicta, long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, and Xarelto, an oral anticoagulant. 2. CHANGES TO MEDICARE PART B: In early August, the Centers for Medicare and Medicaid Services gave new authority to Medicare Advantage plans that allows those plans to negotiate lower drug prices. The policy will also allow Medicare Advantage plans to cross-manage across Part B and Part D as applicable. Credit Suisse analyst A.J. Rice said at the time that the changes could mean a source of potential savings opportunities for MA plans, but a lack of clarity around formal rule making related to step therapy, shared savings arrangement and beneficiaries adoption could limit participation for the 2019 plan year. Long-term, Rice sees these changes as a "net positive" for MA plans vs. Medicare Fee-for-Service. Rice also noted that, according to CMS, in 2016, seven drugs had reported total annual spending in excess of $1B under Part B, including Regeneron's (REGN) Eylea, Amgen's (AMGN) Neulasta and Prolia, Roche's (RHHBY) Avastin, Rituxan and Lucentis, and Johnson & Johnson's Remicade. 3. HEART FAILURE STUDIES MISS ENDPOINTS: In late August, Johnson & Johnson's Janssen Pharmaceuticals announced the results of the Phase 3 Mariner and Commander heart failure studies, which were presented at the European Society of Cardiology Congress 2018 and simultaneously published in The New England Journal of Medicine. In both studies, there was no significant difference found between Xarelto and placebo for the primary efficacy endpoints. Xarelto did, however, demonstrate a consistent safety profile, Janssen said in a statement. Mariner demonstrated that Xarelto did not reduce the composite endpoint of venous thromboembolism, or blood clots, and VTE-related death in acute medically ill patients following hospital discharge. 4. TALC CASE UPDATE: Late last week a jury in New Jersey cleared Johnson & Johnson of liability in a case where a woman claimed that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.

JNJ

Johnson & Johnson

$134.83

1.05 (0.78%)

REGN

Regeneron

$380.46

-3.74 (-0.97%)

AMGN

Amgen

$198.05

0.7 (0.35%)

RHHBY

Roche

$0.00

(0.00%)

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 24

    Dec

  • 28

    Apr

  • 13

    May

JNJ Johnson & Johnson
$134.83

1.05 (0.78%)

10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
10/03/18
WBLR
10/03/18
NO CHANGE
WBLR
Outperform
Janssen termination inconsequential for Aduro Biotech, says William Blair
William Blair analyst Matt Phipps attributes the 13% pullback yesterday in shares of Aduro Biotech (ADRO) to the termination of the company's collaboration with Johnson & Johnson's (JNJ) Janssen Biotech. Janssen officially ended a license agreement for two strains of Aduro's engineered Listeria therapy for lung and prostate cancers. Based on prior data with the Listeria strains and Aduro's decision to discontinue internal development of this platform at the end of 2017, Janssen's decision is not surprising, Phipps tells investors in a research note. The analyst views the news as inconsequential for Aduro and notes he did not consider the program a driver of Aduro valuation. The analyst did not include any aspect of the program in his estimates for Aduro and keeps an Outperform rating on the shares.
10/04/18
PIPR
10/04/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead price target raised to $25 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead (ARWR) to $25 from $17 after the company signed a license and collaboration agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceuticals to develop and commercialize ARO-HBV and up to 3 new TRiM candidates. The analyst notes that Arrowhead will receive $175M cash up front, a $75M equity investment, up to $3.5B in milestones plus up to mid-teens royalties on ARO-HBV. Tenthoff views this deal as transformative for Arrowhead, dramatically strengthening the balance sheet and finding a strong partner for ARO-HBV, while retaining the rest of TRiM pipeline. He reiterates an Overweight rating on Arrowhead's shares.
10/04/18
CANT
10/04/18
NO CHANGE
Target $24
CANT
Overweight
Arrowhead price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kim raised his price target for Arrowhead (ARWR) to $24 from $18 following a newly announced collaboration and license agreement with Johnson & Johnson's (JNJ) subsidiary Janssen. Overall, the analyst feels the agreement is positive for the company as the support of a large partner could speed up the development timelines, increase market penetration with expertise, and validates the TRiM platform that Arrowhead uses. The additional cash will support Arrowhead's internal clinical development, he adds. Kim reiterates an Overweight rating on Arrowhead's shares.
REGN Regeneron
$380.46

-3.74 (-0.97%)

10/11/18
PIPR
10/11/18
NO CHANGE
Target $450
PIPR
Overweight
Piper remains buyer of Regeneron ahead of October 20 FDA action date
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Regeneron Pharmaceuticals (REGN) ahead of the Dupixent asthma October 20 FDA action date. With consensus expecting this indication to contribute well over $1B in revenue in coming years, approval is a "critical near-term catalyst" for the shares, Raymond tells investors in a research note. The analyst adds that while some investors have expressed angst over the breadth of the label, namely restricting use to eosinophilic asthma, he believes recent Sanofi (SNY) commentary provides reason for optimism. The totality of clinical data and the biology behind Dupixent supports a broad label, Raymond contends. He maintains an Overweight rating on Regeneron with a $450 price target.
10/01/18
LEER
10/01/18
NO CHANGE
Target $512
LEER
Outperform
Regeneron price target raised to $512 from $506 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $512 from $506 after the FDA approved the jointly developed and commercialized REGN/SNY PD-1 antibody cemiplimab, now known as Libtayo. The analyst reiterates an Outperform rating on the shares.
10/01/18
CANT
10/01/18
INITIATION
Target $415
CANT
Neutral
Regeneron initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Regeneron Pharmaceuticals with a Neutral rating and $415 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.
AMGN Amgen
$198.05

0.7 (0.35%)

09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
10/01/18
CANT
10/01/18
INITIATION
Target $223
CANT
Neutral
Amgen initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Amgen with a Neutral rating and $223 price target.
RHHBY Roche
$0.00

(0.00%)

10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.

TODAY'S FREE FLY STORIES

ANTM

Anthem

$260.28

7.12 (2.81%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Hot Stocks
Anthem raises FY19 operating cash flow view to greater than $5.5B »

Prior view was greater…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CMG

Chipotle

$831.69

-20.195 (-2.37%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HCM

Hutchison China MediTech

$20.33

0.27 (1.35%)

06:17
10/23/19
10/23
06:17
10/23/19
06:17
Initiation
Hutchison China MediTech initiated  »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPL

PPL Corp.

$32.74

0.09 (0.28%)

06:15
10/23/19
10/23
06:15
10/23/19
06:15
Upgrade
PPL Corp. rating change  »

PPL Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

MNOV

MediciNova

$7.94

-0.235 (-2.88%)

06:15
10/23/19
10/23
06:15
10/23/19
06:15
Hot Stocks
MediciNova receives notice of allowance for new patent covering MN-001 »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.00

-0.58 (-3.98%)

06:14
10/23/19
10/23
06:14
10/23/19
06:14
Recommendations
Snap analyst commentary  »

Barclays ups Snap target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

EVR

Evercore Partners

$78.99

0.22 (0.28%)

06:13
10/23/19
10/23
06:13
10/23/19
06:13
Earnings
Evercore Partners reports Q3 adjusted EPS $1.26, consensus $1.63 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

FCFS

First Cash Financial

$94.76

-0.19 (-0.20%)

06:13
10/23/19
10/23
06:13
10/23/19
06:13
Hot Stocks
First Cash Financial raises quarterly dividend 8% to 27c from 25c per share »

To be paid on November 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NSANY

Nissan

$0.00

(0.00%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Periodicals
Nissan set to axe Datsun brand, drop unprofitable products, Reuters reports »

Nissan is likely to kill…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCFS

First Cash Financial

$94.76

-0.19 (-0.20%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Earnings
First Cash Financial backs FY19 adjusted EPS view $3.85-$4.00 

FY19 consensus $3.90.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LBRT

Liberty Oilfield Services

$8.74

0.07 (0.81%)

06:12
10/23/19
10/23
06:12
10/23/19
06:12
Initiation
Liberty Oilfield Services initiated  »

Liberty Oilfield Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CE

Celanese

$119.23

-2.145 (-1.77%)

06:11
10/23/19
10/23
06:11
10/23/19
06:11
Recommendations
Celanese analyst commentary  »

Celanese price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HLT

Hilton

$90.81

-1.57 (-1.70%)

06:11
10/23/19
10/23
06:11
10/23/19
06:11
Earnings
Hilton sees Q4 adjusted EPS 91c-96c, consensus 99c »

Sees Q4 management and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

FCFS

First Cash Financial

$94.76

-0.19 (-0.20%)

06:10
10/23/19
10/23
06:10
10/23/19
06:10
Earnings
First Cash Financial reports Q3 adjusted EPS 84c, consensus 84c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

DIS

Disney

$132.44

2.16 (1.66%)

06:10
10/23/19
10/23
06:10
10/23/19
06:10
Periodicals
Disney defends Marvel movies, discusses succession planning, WSJ reports »

Disney CEO Robert Iger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

HLT

Hilton

$90.81

-1.57 (-1.70%)

06:10
10/23/19
10/23
06:10
10/23/19
06:10
Earnings
Hilton raises FY19 adjusted EPS view to $3.81-$3.86 from $3.78-$3.85 »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

BIIB

Biogen

$281.96

58.39 (26.12%)

06:09
10/23/19
10/23
06:09
10/23/19
06:09
Upgrade
Biogen rating change  »

Biogen upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$46.15

-1.1 (-2.33%)

06:08
10/23/19
10/23
06:08
10/23/19
06:08
Initiation
Crowdstrike initiated  »

Nomura Instinet starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AXLA

Axcella

$5.23

-0.075 (-1.42%)

06:07
10/23/19
10/23
06:07
10/23/19
06:07
Conference/Events
Axcella management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 08

    Nov

BANC

Banc of California

$15.02

-0.015 (-0.10%)

06:07
10/23/19
10/23
06:07
10/23/19
06:07
Earnings
Banc of California reports Q3 EPS (45c), consensus (34c) »

The net loss available to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

HLT

Hilton

$90.81

-1.57 (-1.70%)

06:07
10/23/19
10/23
06:07
10/23/19
06:07
Earnings
Hilton reports Q3 adjusted EPS $1.05, consensus $1.02 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

06:07
10/23/19
10/23
06:07
10/23/19
06:07
Earnings
Thermo Fisher raises FY19 adj. EPS view to $12.28-$12.34 from $12.16-$12.26 »

Consensus $12.25. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 02

    Dec

  • 07

    Dec

FB

Facebook

$182.27

-7.55 (-3.98%)

06:07
10/23/19
10/23
06:07
10/23/19
06:07
Hot Stocks
Facebook to tell Congress that Libra to 'extend America's financial leadership' »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

ANTM

Anthem

$260.28

7.12 (2.81%)

06:06
10/23/19
10/23
06:06
10/23/19
06:06
Hot Stocks
Anthem sees FY19 medical membership approximately 41M »

Medical membership is now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CMG

Chipotle

$831.69

-20.195 (-2.37%)

06:06
10/23/19
10/23
06:06
10/23/19
06:06
Recommendations
Chipotle analyst commentary  »

Chipotle bull case…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.